Official Home Page of the Apellis Pharmaceuticals Corporate ...
WEBApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
6 things to know about Apellis’ eye drug ahead of FDA decision
WEBFeb 1, 2023 · Here are six things to know — or ponder — about the Apellis drug, called pegcetacoplan, its blockbuster commercial potential, and the series of unusual events that have generated spirited ...
About Apellis - Advancing Treatment by Inhibiting the ...
WEBApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Our Pipeline - Therapeutics for Ophthalmology ... - Apellis
WEBAt Apellis, we aim to transform treatment across a broad range of debilitating diseases driven by complement. We brought forward the first new class of complement medicine in 15 years with the approval of the first targeted C3 therapy.
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for ...
WEB1 day ago · Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases ...
Europe's CHMP turns down Apellis' pegcetacoplan appeal ...
WEB1 day ago · Apellis has spent much of the year appealing the agency’s decisions. Apellis is “deeply disappointed” by the latest rejection, the company’s co-founder and CEO, Cedric Francois, M.D., Ph.D ...
Apellis Drug Becomes First Approved Therapy for Vision-Loss ...
WEBFeb 17, 2023 · The FDA approved Apellis Pharmaceuticals’ Syfovre as a treatment for geographic atrophy, a retinal disorder that is a leading cause of blindness.